Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study

Br J Haematol. 2013 Apr;161(2):280-2. doi: 10.1111/bjh.12204. Epub 2013 Jan 7.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Azacitidine / administration & dosage*
  • Cytarabine / administration & dosage
  • Female
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality*
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / mortality*
  • Registries*
  • Retrospective Studies

Substances

  • Antimetabolites, Antineoplastic
  • Cytarabine
  • Azacitidine